Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.
Cancer Immunol Res
; 12(6): 719-730, 2024 Jun 04.
Article
en En
| MEDLINE
| ID: mdl-38558120
ABSTRACT
Small-cell lung cancer (SCLC) is an aggressive cancer for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives for ICI-resistant tumors, but not all patients with SCLC are responsive. Herein, to integrate CD137 costimulatory function into a T-cell engager format and thereby augment therapeutic efficacy, we generated a CD3/CD137 dual-specific Fab and engineered a DLL3-targeted trispecific antibody (DLL3 trispecific). The CD3/CD137 dual-specific Fab was generated to competitively bind to CD3 and CD137 to prevent DLL3-independent cross-linking of CD3 and CD137, which could lead to systemic T-cell activation. We demonstrated that DLL3 trispecific induced better tumor growth control and a marked increase in the number of intratumoral T cells compared with a conventional DLL3-targeted bispecific T-cell engager. These findings suggest that DLL3 trispecific can exert potent efficacy by inducing concurrent CD137 costimulation and provide a promising therapeutic option for SCLC.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Linfocitos T
/
Complejo CD3
/
Péptidos y Proteínas de Señalización Intracelular
/
Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral
/
Carcinoma Pulmonar de Células Pequeñas
/
Neoplasias Pulmonares
/
Proteínas de la Membrana
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Cancer Immunol Res
Año:
2024
Tipo del documento:
Article
País de afiliación:
Japón